Compare · DXCM vs MMSI
DXCM vs MMSI
Side-by-side comparison of DexCom Inc. (DXCM) and Merit Medical Systems Inc. (MMSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MMSI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 7.3x MMSI ($3.85B).
- Over the past year, DXCM is down 14.9% and MMSI is down 32.0% - DXCM leads by 17.0 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 14 for MMSI).
- DXCM has more recent analyst coverage (25 ratings vs 15 for MMSI).
- Company
- DexCom Inc.
- Merit Medical Systems Inc.
- Price
- $72.84+0.38%
- $64.51+2.32%
- Market cap
- $28.11B
- $3.85B
- 1M return
- +20.73%
- +4.65%
- 1Y return
- -14.94%
- -31.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 14
- Recent ratings
- 25
- 15
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Merit Medical Systems Inc.
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest MMSI
- SEC Form SD filed by Merit Medical Systems Inc.
- Director Gunderson Thomas J. exercised 21,250 shares at a strike of $52.17, increasing direct ownership by 54% to 60,741 units (SEC Form 4)
- Director Ward Lynne N. was granted 3,457 shares, increasing direct ownership by 44% to 11,266 units (SEC Form 4)
- Director Ward Scott R. was granted 3,457 shares (SEC Form 4)
- Director Gunderson Thomas J. was granted 3,457 shares, increasing direct ownership by 10% to 39,491 units (SEC Form 4)
- Director Evans Stephen C. was granted 3,457 shares, increasing direct ownership by 51% to 10,266 units (SEC Form 4)
- Director Kaiser Laura S. was granted 3,457 shares, increasing direct ownership by 35% to 13,352 units (SEC Form 4)
- Director Perez Silvia M. was granted 3,457 shares, increasing direct ownership by 75% to 8,040 units (SEC Form 4)
- Director Carpenter Lonny J. was granted 3,457 shares, increasing direct ownership by 20% to 20,824 units (SEC Form 4)
- Director Mcdonnell Michael R. was granted 3,457 shares, increasing direct ownership by 54% to 9,852 units (SEC Form 4)